Benign lesions such as leukoplakia, solitary varix, hyperkeratosis, heterotopic gastric mucosa, esophagitis, and dysplasia should be discriminated from esophagus cancer, especially from mucosal cancer (ep-cancer, mm cancer). Those benign lesions can be split into three categories. 1. Lesions to be differentiated by ordinary observation. 2. Lesions to be differentiate by the lugol solution. 3. Lesions to be differentiated by biopsy. These benign lesions except for leukoplakia, solitary varix are not stained by lugol solution (as are not cancer lesions), so biopsy is indispensible. Findings of ep cancer and mm cancer are usually very slight and so could be easily missed in ordinary observation. Therefore when we discern suspective lesions almost imperceptive to a naked eye and unstained by lugol solution, or a slightly raised plateau, vague reddening, discoloration or slight unevenness, detection of esophagus cancer at the earliest stage becomes possible. Differential diagnosis also becomes possible.
Download full-text PDF |
Source |
---|
Medicina (Kaunas)
December 2024
Lucid Diagnostics Inc., New York, NY 10017, USA.
Barrett's Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard (EG) is a commercially available biomarker assay used to analyze esophageal cells collected non-endoscopically with EsoCheck (EC) for the qualitative detection of BE/EAC.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
Dow Medical College, Dow University of Health Sciences, Karachi 74200, Pakistan.
: Barrett's esophagus (BE), with metaplastic columnar epithelium in the lower esophagus, predisposes patients to esophageal adenocarcinoma (EAC). Despite extensive research, mechanisms underlying BE progression to EAC remain unclear, and no validated biomarkers are available for clinical use. Progastricsin/Pepsinogen-C (PGC), an aspartic proteinase linked to maintaining normal epithelial morphology, is often absent in advanced gastrointestinal malignancies.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo 113-8677, Japan.
Background/objectives: Superficial esophageal cancer is diagnosed by evaluating the vascular architecture, including dilation, tortuosity, caliber change, and shape, of a lesion. However, this diagnosis is subjective and requires extensive experience. Endoscopically distinguishing squamous intraepithelial neoplasia (SIN) from esophageal cancer is difficult.
View Article and Find Full Text PDFBiomolecules
December 2024
Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
In homeostatic conditions, the basal progenitor cells of the esophagus differentiate into a stratified squamous epithelium. However, in the setting of acid exposure or inflammation, there is a marked failure of basal cell differentiation, leading to basal cell hyperplasia. We have previously shown that lysyl oxidase (LOX), a collagen crosslinking enzyme, is upregulated in the setting of allergic inflammation of the esophagus; however, its role beyond collagen crosslinking is unknown.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ), Network Partner Site, 48149 Münster, Germany.
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of aggressive B-cell lymphoma with a predominant onset in young patients. The minimization of potential (late) side effects is of cardinal interest for these patients. An anticipation of the individual risk profile is desirable to counsel the patient on the putative impact of radiotherapy (RT).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!